A detailed history of J. Goldman & CO LP transactions in Petros Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 31,250 shares of PTPI stock, worth $10,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,250
Holding current value
$10,625
% of portfolio
0.0%

Shares

0 transactions
Quarter Operation Price Per share shares change shares Held SEC Form

About Petros Pharmaceuticals, Inc.


  • Ticker PTPI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 20,708,000
  • Market Cap $7.04M
  • Description
  • Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for th...
More about PTPI
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.